Results 31 to 40 of about 131,281 (256)

Acute myocardial infarction in a patient of infective endocarditis

open access: yesJournal of Pediatric Critical Care, 2015
Infective endocarditis (IE) is associated with a number of complications. Peripheral systemic embolism is a common and serious complication of infective endocarditis linked to migration of vegetation.
Prabhas Prasun Giri   +2 more
doaj   +1 more source

Thromboembolic events in patients with inflammatory bowel disease

open access: yesThe Saudi Journal of Gastroenterology, 2016
Background/Aims: Inflammatory bowel disease (ulcerative colitis and Crohn's disease) is characterized by a chronic inflammatory condition, and is accompanied by abnormalities in coagulation and a hyper-coagulable state.
Farjah H Algahtani   +7 more
doaj   +1 more source

Risk of heparinoid use in cosmetics and moisturizers in individuals vaccinated against severe acute respiratory syndrome coronavirus 2

open access: yesThrombosis Journal, 2021
Recently, heparin-induced thrombocytopenia (HIT) after vaccination with the vaccines manufactured by AstraZeneca and Pfizer–BioNTech has been published in the New England Journal of Medicine.
Kenji Yamamoto
doaj   +1 more source

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis

open access: yesHematological Oncology, Volume 40, Issue 5, Page 1020-1029, December 2022., 2022
Abstract In this subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285), we evaluated efficacy and safety of the anti‐CD38 monoclonal antibody isatuximab (Isa) in combination with carfilzomib‐dexamethasone (Isa‐Kd) versus Kd in older (≥70 years of age, n = 86) and younger (<70 years, n = 216) patients with relapsed multiple myeloma (MM).
Thierry Facon   +15 more
wiley   +1 more source

Direct Oral Anticoagulants for the Treatment of Unusual-Site Venous Thrombosis: An Update

open access: yesPharmaceutics
Direct oral anticoagulants (DOACs) have emerged as the preferred oral anticoagulant therapy for patients with deep vein thrombosis of the lower extremities and pulmonary embolism. DOACs offer several advantages over vitamin K antagonists, including fixed
Anabel Franco-Moreno   +4 more
doaj   +1 more source

Proteus Syndrome: A Rare Case in An Adult Ward

open access: yesEuropean Journal of Case Reports in Internal Medicine, 2021
Proteus syndrome is an extremely rare disorder that manifests as an asymmetric, disproportionate overgrowth of any connective tissue, such as bone, fat or epidermal nevi, in a mosaic or patchy pattern.
Catarina Duarte Santos   +6 more
doaj   +1 more source

Inflammatory bowel disease and superior mesenteric artery thromboembolism [PDF]

open access: yesIntestinal Research, 2020
While patients with inflammatory bowel disease are known to be at increased risk of venous thromboembolism, the risk of arterial thrombosis is less well recognized.
Steven Nicolaides   +2 more
doaj   +1 more source

Deep Vein Thrombosis as an Initial Symptom of Malignant Tumor: A Case Report of Angiosarcoma in the Iliac Vein

open access: yesCase Reports in Oncology, 2021
Although deep vein thrombosis, as well as subsequent pulmonary embolism, is one of the major and fatal complications in cases of malignant neoplasm, it most often occurs after the diagnosis or treatment of the tumor.
Takahiro Matsui   +2 more
doaj   +1 more source

Improving VTE Identification through Adaptive NLP Model Selection and Clinical Expert Rule-based Classifier from Radiology Reports [PDF]

open access: yes2023 International Conference on Bioinformatics and Biomedicine (BIBM), 2023
Rapid and accurate identification of Venous thromboembolism (VTE), a severe cardiovascular condition including deep vein thrombosis (DVT) and pulmonary embolism (PE), is important for effective treatment. Leveraging Natural Language Processing (NLP) on radiology reports, automated methods have shown promising advancements in identifying VTE events from
arxiv  

Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open‐Label, Phase 1 Trial

open access: yesArthritis Care &Research, EarlyView.
Objective This work aimed to evaluate the pharmacokinetics, efficacy, and safety of upadacitinib, an oral selective JAK inhibitor, in pediatric patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods In an open‐label, phase 1 study (SELECT‐YOUTH), enrolled patients, aged 2 to <18 years with pcJIA, received body weight–based ...
Hermine I. Brunner   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy